Debating the Risks of Animal-to-Human Organ Transplants
Debate continues swirling around the issues of animal-to-human organ transplant, stirring up ethical concerns as well as scientific ones. This much is certain: the companies involved in the area saw potential problems coming a long time ago, but placed bets they hoped would establish them as leaders in a new and lucrative market. Those bets may yet pay off, but the players will now be watched far more closely than they were just a few years ago.
You may also be interested in...
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
Viatris’ Mylan has received a positive opinion from the EMA’s CHMP for its bevacizumab biosimilar rival to Avastin under two different names. Meanwhile, Accord has received an endorsement for a generic version of Zytiga.